SynthesisFrontiers in endocrinology2025
Prevalence and risk of thyroid disease among adult primary aldosteronism patients: a systematic review, meta-analysis, and trial sequential analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary aldosteronism (PA), the most prevalent curable secondary hypertension, and thyroid diseases (the second most common endocrine disorder) are increasingly linked, yet their mechanistic connections remain unclear. Design and methods: Four databases (PubMed, Embase, Web of Science, Cochrane Library) were searched for case-control studies. Random-effects meta-analysis and subgroup analyses for thyroid disease subtypes were performed. Sensitivity/trial sequential analyses and Begg's test evaluated robustness/publication bias. Results: Our meta-analysis included five case-control studies, encompassing 1,368 patients with primary aldosteronism (PA) and 6,774 controls. While the overall prevalence of thyroid diseases was higher in PA patients (OR: 1.33, 95% CI: 1.03-1.71, p=0.03), subgroup analysis revealed that this association was primarily driven by a significantly increased prevalence of thyroid nodules (OR: 1.85, 95% CI: 1.23-2.80, p=0.003). No statistically significant associations were found between PA and other specific thyroid conditions, including hyperthyroidism, hypothyroidism, thyroiditis, or thyroid cancer (all p > 0.05). Conclusions: This first meta-analysis demonstrates a significant PA-thyroid disease association. The elevated overall risk of thyroid disease in PA patients appears to be largely attributable to the high burden of thyroid nodules. These findings suggest that patients with PA may benefit from targeted screening for thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.